---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-178718"
form_type: "8-K"
ticker: "OGN"
cik: "0001821825"
company_name: "Organon & Co."
filed_at: "2026-04-27T23:59:59+00:00"
generated_at: "2026-05-15T03:54:29.277599+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Sun Pharma to acquire Organon for $14.00/share in all-cash deal; EV $11.75B

## Summary
- Acquisition price $14.00/share in cash, a 103% premium to Organon's closing price on April 9, 2026.
- Enterprise value of $11.75B; combined revenue of $12.4B (Sun Pharma FY24-25 and Organon CY2025).
- Transaction approved by both boards; subject to Organon stockholder vote and regulatory approvals.
- Joseph Morrissey appointed permanent CEO of Organon; Carrie Cox appointed permanent Executive Chair.
- Sun Pharma secured committed financing; pro forma Net Debt/EBITDA of 2.3x expected.

## SEC filing metadata
- accession: 0001193125-26-178718
- form_type: 8-K
- ticker: OGN
- cik: 0001821825
- company_name: Organon & Co.
- filed_at: 2026-04-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821825/000119312526178718/0001193125-26-178718-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821825/000119312526178718/d38652d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-178718
- JSON: https://secwatch.observer/filing/0001193125-26-178718.json
- Plain text: https://secwatch.observer/filing/0001193125-26-178718.txt

## Source-grounded claims
- claim_id: 85a8e508818ea768029699bf901ddcb580e84024
  claim: Organon & Co. entered into Agreement and Plan of Merger with Sun Pharmaceutical Holdings USA, Inc., Sun Pharma America, Inc., Sun Pharmaceutical Industries Limited, Sun Pharma Canada Inc., Sun Pharma (Netherlands) B.V. (effective 2026-04-26).
  evidence_excerpt: On April 26, 2026, Organon & Co. (the “ Company ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Sun Pharmaceutical Holdings USA, Inc., a Delaware corporation (“ Parent ”), Sun Pharma America, Inc., a Delaware corporation and wholly owned subsidiary of Parent and/or its affiliates (“ Merger Sub ”) and, solely for the purposes of certain covered provisions of the Merger Agreement, Sun Pharmaceutical Industries Limited, an entity organized under the laws of India (“ India Parent ”), Sun Pharma Canada Inc., a corporation incorporated under the laws of the Province of Ontario and Sun Pharma (Netherlands) B.V., a private company with limited liability incorporated under the laws of the Netherlands, pursuant to which, among other things, Merger Sub will merge with and into the Company (the “ Merger ”), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1821825/000119312526178718/0001193125-26-178718-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.